杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/08/19 | 1,833 | 1,849 | 1,827 | 1,842 | +9 | +0.5% | 94,100 |
2021/08/18 | 1,822 | 1,838 | 1,819 | 1,833 | +14 | +0.8% | 58,400 |
2021/08/17 | 1,824 | 1,830 | 1,814 | 1,819 | +4 | +0.2% | 63,600 |
2021/08/16 | 1,826 | 1,826 | 1,802 | 1,815 | -12 | -0.7% | 61,200 |
2021/08/13 | 1,808 | 1,827 | 1,802 | 1,827 | +21 | +1.2% | 66,600 |
2021/08/12 | 1,811 | 1,814 | 1,801 | 1,806 | +3 | +0.2% | 52,400 |
2021/08/11 | 1,800 | 1,807 | 1,791 | 1,803 | +13 | +0.7% | 103,500 |
2021/08/10 | 1,771 | 1,790 | 1,771 | 1,790 | +17 | +1% | 78,200 |
2021/08/06 | 1,778 | 1,789 | 1,764 | 1,773 | -2 | -0.1% | 82,400 |
2021/08/05 | 1,751 | 1,792 | 1,746 | 1,775 | +20 | +1.1% | 85,600 |
2021/08/04 | 1,750 | 1,766 | 1,731 | 1,755 | -45 | -2.5% | 157,700 |
2021/08/03 | 1,818 | 1,818 | 1,796 | 1,800 | -9 | -0.5% | 31,600 |
2021/08/02 | 1,784 | 1,811 | 1,777 | 1,809 | +38 | +2.1% | 82,600 |
2021/07/30 | 1,780 | 1,781 | 1,762 | 1,771 | -18 | -1% | 99,100 |
2021/07/29 | 1,797 | 1,805 | 1,780 | 1,789 | -9 | -0.5% | 84,800 |
2021/07/28 | 1,772 | 1,804 | 1,772 | 1,798 | +13 | +0.7% | 96,000 |
2021/07/27 | 1,801 | 1,803 | 1,777 | 1,785 | -35 | -1.9% | 138,200 |
2021/07/26 | 1,830 | 1,830 | 1,810 | 1,820 | +11 | +0.6% | 60,100 |
2021/07/21 | 1,842 | 1,842 | 1,803 | 1,809 | +7 | +0.4% | 90,700 |
2021/07/20 | 1,783 | 1,805 | 1,782 | 1,802 | +5 | +0.3% | 74,700 |
2021/07/19 | 1,785 | 1,799 | 1,779 | 1,797 | -5 | -0.3% | 62,900 |
2021/07/16 | 1,796 | 1,808 | 1,790 | 1,802 | -11 | -0.6% | 58,400 |
2021/07/15 | 1,829 | 1,839 | 1,806 | 1,813 | -12 | -0.7% | 99,300 |
2021/07/14 | 1,814 | 1,829 | 1,806 | 1,825 | +17 | +0.9% | 77,500 |
2021/07/13 | 1,809 | 1,812 | 1,796 | 1,808 | +4 | +0.2% | 85,300 |
2021/07/12 | 1,781 | 1,804 | 1,778 | 1,804 | +45 | +2.6% | 114,000 |
2021/07/09 | 1,727 | 1,765 | 1,725 | 1,759 | +6 | +0.3% | 188,500 |
2021/07/08 | 1,763 | 1,767 | 1,753 | 1,753 | -19 | -1.1% | 132,400 |
2021/07/07 | 1,788 | 1,788 | 1,765 | 1,772 | -19 | -1.1% | 168,100 |
2021/07/06 | 1,817 | 1,817 | 1,787 | 1,791 | -14 | -0.8% | 133,700 |
2021/07/05 | 1,830 | 1,834 | 1,805 | 1,805 | -25 | -1.4% | 91,000 |
2021/07/02 | 1,836 | 1,841 | 1,826 | 1,830 | -2 | -0.1% | 113,700 |
2021/07/01 | 1,823 | 1,833 | 1,818 | 1,832 | +20 | +1.1% | 140,400 |
2021/06/30 | 1,822 | 1,825 | 1,801 | 1,812 | +4 | +0.2% | 151,800 |
2021/06/29 | 1,801 | 1,814 | 1,789 | 1,808 | -9 | -0.5% | 155,300 |
2021/06/28 | 1,815 | 1,819 | 1,801 | 1,817 | +10 | +0.6% | 139,600 |
2021/06/25 | 1,813 | 1,817 | 1,794 | 1,807 | +14 | +0.8% | 286,000 |
2021/06/24 | 1,764 | 1,799 | 1,764 | 1,793 | +39 | +2.2% | 337,700 |
2021/06/23 | 1,753 | 1,771 | 1,750 | 1,754 | +6 | +0.3% | 184,100 |
2021/06/22 | 1,732 | 1,749 | 1,719 | 1,748 | +42 | +2.5% | 210,700 |
2021/06/21 | 1,705 | 1,719 | 1,699 | 1,706 | -24 | -1.4% | 173,300 |
2021/06/18 | 1,746 | 1,754 | 1,730 | 1,730 | -15 | -0.9% | 194,500 |
2021/06/17 | 1,760 | 1,763 | 1,740 | 1,745 | -6 | -0.3% | 104,300 |
2021/06/16 | 1,744 | 1,754 | 1,734 | 1,751 | +8 | +0.5% | 95,800 |
2021/06/15 | 1,746 | 1,748 | 1,728 | 1,743 | -13 | -0.7% | 171,800 |
2021/06/14 | 1,750 | 1,756 | 1,743 | 1,756 | +16 | +0.9% | 88,900 |
2021/06/11 | 1,750 | 1,753 | 1,731 | 1,740 | -5 | -0.3% | 168,000 |
2021/06/10 | 1,750 | 1,756 | 1,734 | 1,745 | +5 | +0.3% | 131,000 |
2021/06/09 | 1,733 | 1,748 | 1,727 | 1,740 | +10 | +0.6% | 110,000 |
2021/06/08 | 1,715 | 1,737 | 1,710 | 1,730 | +37 | +2.2% | 169,600 |
801~
850
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム